The FDA approval of Icotyde (icotrokinra) on March 18, 2026, as the first oral IL-23 receptor antagonist, has fundamentally reshaped the psoriasis treatment landscape. For patients choosing between oral and injectable therapies, comparing Icotyde, Skyrizi, and Otezla is no longer just academic — it's a practical decision with real-world implications. This guide breaks down the key differences, efficacy, safety, and switching pathways to help you make an informed choice.
Quick Comparison: What Sets These Three Apart
These three treatments represent distinct philosophies in psoriasis management. Icotyde is the first oral option with biologic-level efficacy, targeting the IL-23 pathway directly. Skyrizi remains the gold standard injectable biologic with proven long-term results. Otezla, a non-immunosuppressive oral PDE4 inhibitor, offers a safer profile for patients who can't tolerate immunosuppression but comes with lower efficacy. The arrival of Icotyde means patients now have a true oral alternative that doesn't sacrifice performance.
Head-to-Head Comparison Table
| Feature | Icotyde (Icotrokinra) | Skyrizi (Risankizumab) | Otezla (Apremilast) |
|---|---|---|---|
| Drug Class | Oral IL-23 receptor antagonist peptide | Injectable IL-23p19 antibody | Oral PDE4 inhibitor |
| Manufacturer | J&J / Protagonist Therapeutics | AbbVie | Amgen |
| FDA Approval | March 2026 | April 2019 | March 2014 |
| How Taken | One 200mg pill daily, empty stomach with water, 30 min before eating | 150mg injection every 12 weeks (after loading doses) | Two 30mg tablets daily |
| IGA 0/1 Rate | ~70% | ~75–80% | ~18% |
| PASI 90 at Week 16 | ~55% | ~70–73% | ~10% |
| Key Side Effects | Mild GI symptoms, close to placebo | Injection site reactions, upper respiratory infections | Nausea, diarrhea, headache |
| Immunosuppression | Targeted IL-23 only | Targeted IL-23 only | None |
Note: Sotyktu (deucravacitinib), a TYK2 inhibitor, achieved ~50% IGA 0/1 but lost head-to-head to Icotyde in Phase 3 trials. Icotyde surpassed Sotyktu in both PASI 90 and IGA 0/1 rates.
Icotyde: The New Oral Option
Icotyde (icotrokinra) is the first oral IL-23 receptor antagonist — technically a constrained cyclic peptide engineered to survive the GI tract and block IL-23 signaling with high specificity. It's taken as a single 200mg tablet once daily on an empty stomach with water, at least 30 minutes before eating.
Approved for moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 years and older (≥40kg), Icotyde demonstrated approximately 70% IGA 0/1 (clear or almost clear skin) and 55% PASI 90 at week 16. In head-to-head trials, Icotyde outperformed Sotyktu (deucravacitinib), which was previously the leading oral option. The safety profile through week 16 was close to placebo, with mild GI symptoms being the most common adverse events. J&J projects over $5 billion in peak annual sales, signaling the industry's confidence in this first-in-class treatment.
Skyrizi: The Injectable Gold Standard
Skyrizi (risankizumab) remains the benchmark injectable IL-23 inhibitor. Administered as a subcutaneous injection every 12 weeks after loading doses at weeks 0 and 4, it delivers 70–73% PASI 90 at week 16 in the UltIMMa trials — with responses often improving further through week 52. In indirect comparisons, Skyrizi maintains superior PASI 90 and PASI 100 rates compared to Icotyde.
The infrequent 12-week dosing interval is among the most convenient for injectable biologics, and years of real-world data support a well-established safety profile. Skyrizi continues to be the go-to choice for patients seeking maximum skin clearance. However, the need for injections remains a barrier for patients with needle phobia or difficulty with self-injection — and that's exactly where Icotyde changes the conversation.
Otezla: The Non-Immunosuppressive Option
Otezla (apremilast) is a non-immunosuppressive oral PDE4 inhibitor taken twice daily at 30mg. While it offers a favorable safety profile with no risk of serious infections or malignancies, its efficacy is significantly lower — only ~18% achieve IGA 0/1 and ~10% reach PASI 90 at week 16. Common side effects include nausea, diarrhea, and headache, which often improve over time.
Otezla is best suited for patients with mild-to-moderate psoriasis or those who cannot use immunosuppressive therapies due to comorbidities like active infections or a history of malignancy. For patients currently on Otezla with inadequate response, Icotyde presents a compelling upgrade — offering significantly better efficacy while maintaining oral administration.
Switching Guidance: Which One Should You Choose?
Choosing between these three requires a personalized approach. Here's a practical decision framework:
- Want maximum clearance and don't mind injections → Skyrizi is still the most effective option available.
- Want a pill with strong clearance (closest to biologic results) → Icotyde is the best oral option in 2026.
- Want a pill with no immunosuppression risk → Otezla remains a safe choice, though with a meaningful efficacy trade-off.
- Currently on Skyrizi but hate injections → Icotyde is the first oral that approaches biologic-level results. Discuss switching with your dermatologist.
- Currently on Otezla with inadequate response → Icotyde offers a significant efficacy boost while keeping you on a pill.
- Currently on Sotyktu → Icotyde beat it head-to-head; talk to your dermatologist about whether switching makes sense.
Switching between any of these treatments should always be done under medical supervision. Washout periods, insurance prior authorization, and individual response history all factor into the decision. For a detailed walkthrough of the switching process, see our guide to switching from injectable to oral psoriasis treatments.
The Bottom Line
Icotyde has transformed the psoriasis treatment landscape by offering the first oral therapy that genuinely competes with injectable biologics in efficacy. Skyrizi remains the gold standard for maximum clearance. Otezla continues to serve patients who must avoid immunosuppression. For patients considering a switch — whether from injection to pill, from a weaker oral to a stronger one, or from one mechanism to another — the options in 2026 are better than they've ever been. For a broader view of emerging treatments, see our 2025–2026 psoriasis treatment outlook.